This study provides evidence of increased glycemic control and patient satisfaction coupled with decreased total insulin requirements and diabetes costs in patients with T2DM initiating V-Go for insulin delivery compared with patients continuing standard insulin delivery. The gene discussed is INS; the disease is diabetes mellitus.